Westmount Partners LLC Acquires 37 Shares of Stryker Co. (NYSE:SYK)

Westmount Partners LLC raised its position in Stryker Co. (NYSE:SYK) by 4.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 882 shares of the medical technology company’s stock after buying an additional 37 shares during the quarter. Westmount Partners LLC’s holdings in Stryker were worth $317,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the company. Dunhill Financial LLC grew its position in shares of Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 37 shares in the last quarter. Centennial Bank AR grew its position in shares of Stryker by 106.7% in the second quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock valued at $32,000 after purchasing an additional 48 shares in the last quarter. Darwin Wealth Management LLC purchased a new position in shares of Stryker in the third quarter valued at $36,000. Hara Capital LLC purchased a new position in shares of Stryker in the third quarter valued at $42,000. Finally, HBW Advisory Services LLC purchased a new position in Stryker during the third quarter worth about $42,000. 77.09% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Truist Financial boosted their target price on Stryker from $380.00 to $409.00 and gave the stock a “hold” rating in a research report on Wednesday, December 18th. Royal Bank of Canada reiterated an “outperform” rating and issued a $425.00 price objective on shares of Stryker in a report on Tuesday, January 7th. Piper Sandler reiterated an “overweight” rating and issued a $420.00 price objective (up from $380.00) on shares of Stryker in a report on Wednesday, October 30th. Citigroup upped their price objective on Stryker from $411.00 to $450.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Finally, StockNews.com raised Stryker from a “hold” rating to a “buy” rating in a research note on Thursday. Four equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to MarketBeat.com, Stryker currently has a consensus rating of “Moderate Buy” and an average price target of $405.80.

Insider Activity

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the sale, the chief executive officer now directly owns 100,027 shares of the company’s stock, valued at $36,879,954.90. The trade was a 36.43 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 5.90% of the company’s stock.

Stryker Stock Down 0.9 %

SYK traded down $3.19 during trading on Monday, hitting $362.47. 593,769 shares of the company’s stock traded hands, compared to its average volume of 1,181,281. The company’s 50 day simple moving average is $375.40 and its two-hundred day simple moving average is $357.95. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66. Stryker Co. has a 12-month low of $307.23 and a 12-month high of $398.20. The stock has a market capitalization of $138.18 billion, a price-to-earnings ratio of 38.85, a PEG ratio of 2.82 and a beta of 0.95.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The firm had revenue of $5.49 billion for the quarter, compared to analysts’ expectations of $5.37 billion. During the same period in the prior year, the firm earned $2.46 EPS. The company’s revenue was up 11.9% compared to the same quarter last year. Analysts predict that Stryker Co. will post 12.06 earnings per share for the current fiscal year.

Stryker Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be given a dividend of $0.84 per share. This is a positive change from Stryker’s previous quarterly dividend of $0.80. The ex-dividend date is Tuesday, December 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.93%. Stryker’s dividend payout ratio (DPR) is presently 36.01%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.